Raymond James analyst Andrew Cooper upgraded Myriad Genetics to Outperform from Market Perform with a $25 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
- Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
- Myriad Genetics appoints Glenn Farrell as CMO
- Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
- Here’s why Natera is jumping in afternoon trading